Impedimetric Tumor Detection System
Revolutionizing Breast Cancer Biopsy with ITDS
The Impedimetric Tumor Detection System (ITDS) is a novel technology in breast cancer biopsy that provides real-time diagnosis using a minimally invasive biopsy procedure. It significantly improves accuracy and patient outcomes compared to traditional methods like FNA and core needle biopsy (CNB).
Smarter Diagnosis for BIRADS-3 and Beyond
Breast abnormalities, categorized from BIRADS-1 to BIRADS-5, guide treatment decisions. BIRADS-3 lesions typically require 3–6 month follow-ups, while BIRADS-4a and higher demand biopsy. ITDS empowers clinicians with immediate risk assessment — minimizing uncertainty and unnecessary delays in managing these cases.
How It Works
A specially designed breast biopsy needle, guided by ultrasound, is inserted into the lesion. The ITDS system sends a low electrical signal to measure tissue impedance. In under 60 seconds, it identifies whether the mass is likely malignant or benign — delivering breast biopsy results in 24 hours or less.
Real-Time Results with High Accuracy
In a study involving 138 masses, ITDS achieved:
-
Sensitivity: 95%
-
Specificity: 89%
-
Accuracy: 90%
This makes ITDS a powerful tool for early detection, reducing false negatives, and enhancing diagnostic precision.
Faster, Smarter Breast Biopsy
Whether you perform a breast biopsy stereotactic or an ultrasound-guided breast biopsy, ITDS integrates seamlessly into your workflow. It supports:
-
Instant malignancy assessment
-
Reduced over-biopsies and surgeries
-
Higher patient confidence and comfort
-
Shorter procedures with faster turnaround
-
No lab delays — just breast biopsy results in under a minute
FAQ: Breast Biopsy – How Long Does It Take?
Traditional biopsies take 15–45 minutes to perform, but pathology results may take days. With ITDS, clinicians receive diagnostic feedback in real time, often within 60 seconds, streamlining decision-making and reducing patient anxiety.
Boosting the Power of the Breast Biopsy Needle
The ITDS uses a sterile, sensor-enabled breast biopsy needle to analyze tissue on the spot. Its precision reduces the need for repeat procedures and adds a new layer of intelligence to everyday biopsy tools.
Enhancing Stereotactic Breast Biopsy
In stereotactic breast biopsy procedures, ITDS delivers real-time tissue analysis during mammography-guided targeting. This enhances accuracy while keeping the procedure quick, low-risk, and minimally invasive.
Hospitech’s Commitment to Cancer Care
Hospitech Cancer Care Innovations leads the way in advanced cancer diagnostics, including:
-
ITDS
-
Cancer Diagnostic Probe (CDP)
-
Electrical Endoscopic Mass Characterizer (EEMC)
-
ElectroChemoTherapy (ECT)
-
Gamma Probe
Backed by clinical trials, global collaborations, and patents, these tools are transforming early cancer detection worldwide.
Conclusion: Better Outcomes for All
With ITDS, healthcare providers can diagnose faster, treat sooner, and give patients peace of mind. It’s a game-changer for any facility offering breast biopsy ultrasound guided, stereotactic biopsy, or advanced cancer screening.
TECHNOLOGY
Technology of (ITDS)
Using ITDS makes it possible to differentiate BI-RADS3 breast masses that require periodic follow-ups from BI-RADS4 and above, which require more examination through biopsy or excision, with higher accuracy than conventional imaging methods. This device’s findings reveal the dielectric properties of cells as a result of their pathophysiological changes during cancer, such as increased cell size, cell membrane permeability, alterations in water content within the cell, and so on. It is primarily employed in the diagnosis of Borderline Breast Diseases. While not all types of masses in this category are inherently malignant, they are more likely to become precancerous or high-risk masses over time compared to other normal breast masses. Therefore, based on breast surgery standards, it is preferable to remove them from the body.
FEATURES
The Impedimetric Tumor Detection System comes with advanced capabilities, including the detection of Borderline Breast Diseases (BBDs), aiding in the early diagnosis of breast cancers, and improving the precision of sampling in large masses by identifying the most pathological area within the mass. This device also incorporates the following features:
Features of (ITDS)
- Assisting radiologists and surgeons identify BI-RADS3 masses requiring sampling or excision.
- Detection of Borderline Breast Diseases (BBDs)
- Helping to diagnose early-stage breast cancers
- Especially beneficial for patients with a family history of breast cancer
- Beneficial for patients having dense fibro glandular breasts (that are challenging cases in mammographically evaluations)
- Beneficial for pregnant women
- Increasing the accuracy of sampling in large masses by determining the most pathological part of the mass
- 93% accuracy in the clinical trial with 138 Breast masses
ACHIEVEMENT
ITDS is a groundbreaking device that has revolutionized the way tumors are detected in the human body. This device has been awarded several US patents for its innovative technology and has been featured in numerous scientific articles showcasing its effectiveness in early tumor detection.
Articles
National Library of Medicine
Nanoscale
Biosensors and bioelectronics
patents
US20220022771A1
US20220015660A1
US20220022947A1
US20220022946A1
CLINIAL TRIAL RESULTS
ITDS has shown promising results in a trial involving 138 breast masses, with a sensitivity of 95%. This means that the
device accurately detected the presence of tumors in 95 out of 100 cases. ITDS could potentially improve the accuracy
and effectiveness of breast cancer screening, leading to earlier diagnosis and better outcomes for patients.
Results
Sensitivity: 95%
Specificity: 89%
Accuracy: 90%
Related products
Reviews
There are no reviews yet.